BiomX Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
HLSQ$0.11-13.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| As of December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | 4,360 | 16,856 |
| Restricted cash | 595 | 958 |
| Property and equipment, held for sale | 157 | - |
| Other current assets | 463 | 2,706 |
| Total current assets | 5,575 | 20,520 |
| Non-current assets | ||
| Non-current restricted cash | - | 161 |
| Operating lease right-of-use assets | - | 5,457 |
| Property and equipment, net | - | 5,045 |
| In-process Research and development (“IPR&D”) asset | 208 | 12,050 |
| Total non-current assets | 208 | 22,713 |
| 5,783 | 43,233 | |
**CONSOLIDATED BALANCE SHEETS
| As of December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Trade account payables | 3,120 | 1,882 |
| Current portion of lease liabilities | 1,436 | 1,130 |
| Other account payables | 1,823 | 5,255 |
| Total current liabilities | 6,379 | 8,267 |
| Non-current liabilities | ||
| Operating lease liabilities, net of current portion | - | 8,454 |
| Other liabilities | - | 77 |
| Warrants | 706 | 2,287 |
| Total non-current liabilities | 706 | 10,818 |
| Commitments and Contingencies (Note 8) | ||
| Stockholders’ equity (capital deficiency) | ||
| Preferred Stock, $0.0001 par value; Authorized - 1,000,000 shares as of December 31, 2025 and December 31, 2024. Issued and outstanding – 147,512 as of December 31, 2025 and 147,735 shares as of December 31, 2024. | 18,617 | 18,645 |
| Common stock, $0.0001 par value (“Common Stock”); Authorized - 750,000,000 shares as of December 31, 2025 and December 31, 2024. Issued and outstanding – 1,593,703 and 1,023,010 as of December 31, 2025 and December 31, 2024, respectively. (*) | 7 | 6 |
| Additional paid in capital | 196,970 | 186,194 |
| Accumulated deficit | (216,896) | (180,697) |
| Total Stockholders’ equity (capital deficiency) | (1,302) | 24,148 |
| 5,783 | 43,233 | |
| (*) | All share amounts have been retroactively adjusted to reflect a 1-for-19 reverse share split as discussed in Note 12A. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.